Rotavirus immunity

"Rotavirus immunity" refers to the complex immune response generated by the body upon exposure to rotavirus, a double-stranded RNA virus responsible for severe gastroenteritis, especially in children. Protection against rotavirus results from a combination of innate immunity (such as interferon and cytokine responses), adaptive antibody-mediated immunity (especially immunoglobulin A against viral proteins VP7 and VP4), and cell-mediated immune responses. Both symptomatic and asymptomatic infections contribute to developing immunity, typically with first infections generating serotype-specific immunity, while subsequent exposures broaden protection across rotavirus types. Current rotavirus vaccines function by stimulating this combined immune response, with serum and mucosal IgA considered correlates of protection, though absolute immune correlates remain incompletely defined. Key issues: - This entry does not specify a molecular entity (such as a protein, receptor, or gene), but instead describes an entire physiological process or immunological state. - Rotavirus immunity is not a direct drug target; instead, specific viral proteins (VP7, VP4) or host pattern recognition receptors (e.g., TLRs, RIG-I, MDA-5) could be considered true molecular targets in the context of therapy or vaccine development[2][3][4]. - Please use specific molecule or viral protein names (e.g., "Rotavirus VP4 protein", "Interferon lambda receptor") for proper target-based information structuring.

Other names

Rotavirus immune responseImmunity to rotavirus